On November 14, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least on prior therapy.
“The approval of zanubrutinib as a second line therapy represents an important advancement for the treatment of mantle cell lymphoma,” said Meghan Gutierrez, Chief Executive Officer for the Lymphoma Research Foundation. “Expanded treatment options can transform the patient experience and provide hope to people living with a mantle cell diagnosis.”
For more information on the FDA approval of zanubrutinib (BRUKINSA), visit the FDA’s website or lymphoma.org/MCLFDAUpdates.
Oral Therapies Learning Center
Oral Therapies Learning CenterCurrently, there are a number of chemotherapy and targeted anticancer drugs approved or under investigation for the treatment of lymphoma that can be taken by mouth, either in liquid or tablet/capsule form. Oral agents are just as effective and can have similar side effects as anticancer drugs that are given intravenously. Learn more >
